Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study

Autor: C.A. Uyl-de Groot, Z. Erjavec, E. (Vera) J. M. Mattijssen, Gerard Vreugdenhil, Kim M. Holtzer-Goor, Eduardus F. M. Posthuma, Simon Daenen, Peter C. Huijgens, P. W. Wijermans, W. G. Peters, H. Visser, M. R. Schaafsma, P. Joosten, S. Wittebol, M. H. J. Van Oers, K. G. van der Hem
Přispěvatelé: Health Technology Assessment (HTA), MUMC+: MA Medische Oncologie (9), Onderwijs instituut FHML, RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, AII - Amsterdam institute for Infection and Immunity, CCA -Cancer Center Amsterdam, Clinical Haematology, Hematology, CCA - Quality of life
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Zdroj: Quality of Life Research, 24(12), 2895-2906. Springer Netherlands
Quality of Life Research, 24(12), 2895-2906. SPRINGER
Holtzer-Goor, K M, Schaafsma, M R, Joosten, P, Posthuma, E F M, Wittebol, S, Huijgens, P C, Mattijssen, E J M, Vreugdenhil, G, Visser, H, Peters, W G, Erjavec, Z, Wijermans, P W, Daenen, S M G J, van der Hem, K G, van Oers, M H J & Uyl-de Groot, C A 2015, ' Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study ', Quality of Life Research, vol. 24, no. 12, pp. 2895-2906 . https://doi.org/10.1007/s11136-015-1039-y
Quality of Life Research, 24(12), 2895-2906. Springer, Cham
Quality of Life Research
Quality of life research, 24(12), 2895-2906. Springer Netherlands
ISSN: 0962-9343
1573-2649
DOI: 10.1007/s11136-015-1039-y
Popis: Purpose To describe the health-related quality of life (HRQoL) of an unselected population of patients with chronic lymphocytic leukaemia (CLL) including untreated patients. Methods HRQoL was measured by the EORTC QLQ-C30 including the CLL16 module, EQ-5D, and VAS in an observational study over multiple years. All HRQoL measurements per patient were connected and analysed using area under the curve analysis over the entire study duration. The total patient group was compared with the general population, and three groups of CLL patients were described separately, i.e. patients without any active treatment (“watch and wait”), chlorambucil treatment only, and patients with other treatment(s). Results HRQoL in the total group of CLL patients was compromised when compared with age- and gender-matched norm scores of the general population. CLL patients scored statistically worse on the VAS and utility score of the EQ-5D, all functioning scales of the EORTC QLQ-C30, and the symptoms of fatigue, dyspnoea, sleeping disturbance, appetite loss, and financial difficulties. In untreated patients, the HRQoL was slightly reduced. In all treatment stages, HRQoL was compromised considerably. Patients treated with chlorambucil only scored worse on the EORTC QLQ-C30 than patients who were treated with other treatments with regard to emotional functioning, cognitive functioning, bruises, uncomfortable stomach, and apathy. Conclusions CLL patients differ most from the general population on role functioning, fatigue, concerns about future health, and having not enough energy. Once treatment is indicated, HRQoL becomes considerably compromised. This applies to all treatments, including chlorambucil, which is considered to be a mild treatment. Electronic supplementary material The online version of this article (doi:10.1007/s11136-015-1039-y) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: